HPV 6, 11, 42/Combo detection doesn't ID CIN 2+, 3+ risk

HPV 6, 11, 42/Combo detection doesn't ID CIN 2+, 3+ risk

(HealthDay)—Detection of human papillomavirus (HPV) 6, 11, 42 or combination infections does not identify increased three-year risk of cervical precancer, according to a study published in the January issue of Obstetrics & Gynecology.

Philip E. Castle, Ph.D., M.P.H., from the Albert Einstein College of Medicine in New York City, and colleagues used data from the New Mexico Human Papillomavirus Pap Registry for a stratified sample of 59,644 residual cervical cytology specimens that underwent HPV genotyping from a population of 379,000 cytology specimens. The three-year cumulative incidence of cervical intraepithelial neoplasia grade 2 or more severe (CIN 2+) and grade 3 or more severe (CIN 3+) was assessed after detection of 581 single or multiple infections of HPV 6, 11, or 42.

The researchers found that there was a 0.8 percent overall prevalence of a single of HPV 6, 11, or 42. After 581 HPV 6, 11, 42, or combinations infections, the three-year risk of CIN 2+ and CIN 3+ were 0.4 and 0.0 percent, respectively. In comparison, after a negative HPV result (27,522 cytologic results), the three-year risks of CIN 2+ and CIN 3+ were 0.2 and 0.1 percent, respectively.

"Testing for HPV 6, 11, 42, or combinations of those types should be discontinued because it has no proven benefit to patients," the authors write.

Roche Molecular Systems provided the Genotyping Test and equipment to automate the HPV genotyping assays. Two authors disclosed financial ties to pharmaceutical and biotechnology companies, including Roche.

More information: Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Is egg freezing an empowering option for women?

Nov 17, 2014

Katie Hammond, a PhD candidate in the Department of Sociology researching the experience of egg donation in Canada, discusses the recent decision by tech giants Facebook and Apple to offer egg freezing to ...

Peripheral nerve blocks OK for migraines in pregnancy

Nov 14, 2014

(HealthDay)—For migraines that do not respond to medications, peripheral nerve blocks may be a treatment option in pregnant women, according to research published online Nov. 5 in Obstetrics & Gynecology.

Hearing the heart of the mother and her baby

Nov 14, 2014

A group of students from the Autonomous Metropolitan University of Mexico (UAM-I) developed a technological portable prototype able to diagnose health conditions in the mother and in the baby by monitoring ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.